MINI FUTURE LONG - NOVO-NORDISK B | Delayed Börse Stuttgart 04:24:26 2024-05-22 EDT | ||
| 22.04 EUR | +0.46% |
|
| Current month | +4.53% | ||
| 1 month | +5.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 22.04 | +0.46% |
| 24-05-21 | 21.94 | +0.32% |
| 24-05-17 | 21.87 | -0.50% |
| 24-05-16 | 21.98 | -0.68% |
| 24-05-15 | 22.13 | -0.14% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 04:24 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PA4CJL |
| ISIN | DE000PA4CJL6 |
| Date issued | 2014-04-09 |
| Strike | 93.44 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.17 € |
|---|---|
| Lowest since issue | 0.39 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
927.2
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.94%
- Stock Market
- Certificates
- Certificat